Endogenous androgens and sex hormone-binding globulin in women and risk of metabolic syndrome and type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 12, 2015, Pages 4595-4603

  Fenske, Benjamin ^a   Kische, Hanna ^a   Gross, Stefan ^b,c   Wallaschofski, Henri ^a,b   Völzke, Henry ^b,c   Dörr, Marcus ^b,c   Nauck, Matthias ^a,b   Keevil, Brian G ^d   Brabant, Georg ^e   Haring, Robin ^a,b,f  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c Medical University of Greifswald   (Germany)

^d University Hospital   (United Kingdom)

^e UNIVERSITY OF LÜBECK   (Germany)

^f University of Applied Sciences Technology Business and Design   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POPULATION RESEARCH; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; TANDEM MASS SPECTROMETRY; VERY ELDERLY; AGE; BLOOD; DIABETES MELLITUS, TYPE 2; GERMANY; INCIDENCE; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PREVALENCE; RISK; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGENS; ANDROSTENEDIONE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; RISK; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; YOUNG ADULT;

EID: 84951159760     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2546     Document Type: Article

References (38)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. Prasad H, Ryan DA, Celzo MF, Stapleton D. Metabolic syndrome: definition and therapeutic implications. Postgrad Med. 2012;124: 21-30.
3. Mogre V, Salifu ZS, Abedandi R. Prevalence, components and associated demographic and lifestyle factors of the metabolic syndrome in type 2 diabetes mellitus. J Diabetes and Metabol Disorders. 2014;13:80.
4. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, et al. Tes-tosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004; 27:1036-1041.
5. Patel SM, Ratcliffe SJ, Reilly MP, et al. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metabol. 2009;94:4776-4784.
6. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 2011;40:189-207.
7. Weinberg ME, Manson JE, Buring JE, et al. Low sex hormonebinding globulin is associated with the metabolic syndrome in postmenopausal women. Metabolism. 2006;55:1473-1480.
8. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
9. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34:528-540.
10. Vikan T, Schirmer H, Njolstad I, Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol. 2010;162:747-754.
11. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial.AmJ Epidemiol. 1996;143:889-897.
12. Kalyani RR, Franco M, Dobs AS, et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab. 2009;94:4127-4135.
13. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and metaanalysis. JAMA. 2006;295:1288-1299.
14. Brand JS, van der Schouw YT. Testosterone, SHBG and cardiovascular health in postmenopausal women. Int J Impotence Res. 2010; 22:91-104.
15. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009;361:1152-1163.
16. Demers LM. Androgen deficiency in women; role of accurate testosterone measurements. Maturitas. 2010;67:39-45.
17. Matsumoto AM, Bremner WJ. Serum testosterone assays-accuracy matters. J Clin Endocrinol Metabol. 2004;89:520-524.
18. Haring R, Spielhagen C, Nauck M. Challenges in the measurement of serum testosterone concentrations as a biomarker of men?s health. J Lab Med. 2011;35:1-5.
19. Volzke H, Alte D, Schmidt CO, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40:294-307.
20. Schwarz S, Volzke H, Alte D, Hoffmann W, John U, Doren M. Gynaecological health care utilization and use of sex hormones-the study of Health in Pomerania. Human Reprod. 2005;20:2916-2922.
21. Alte D, Luedemann J, Rose HJ, John U. Laboratory markers carbohydrate- deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume are not useful as screening tools for highrisk drinking in the general population: results from the Study of Health in Pomerania (SHIP). Alcoh Clin Exp Res. 2004;28:931-940.
22. Schwarz S, Volzke H, Alte D, et al. Menopause and determinants of quality of life in women at midlife and beyond: the study of health in pomerania (SHIP). Menopause. 2007;14:123-134.
23. Haring R, Hannemann A, John U, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2012;97:408-415.
24. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
25. Alberti KG, Eckel RH, Grundy SM, et al. 2009 Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 120:1640-1645.
26. Lidfeldt J, Nyberg P, Nerbrand C, Samsioe G, Schersten B, Agardh CD. Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study. Diabetes Obes Metab. 2003;5:106-112.
27. Thienpont LM, Van Uytfanghe K, Blincko S, et al. State-of-the-art of serum testosterone measurement by isotope dilution-liquid chromatography- tandem mass spectrometry. Clin Chem. 2008;54: 1290-1297.
28. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
29. Sutton-Tyrrell K, Wildman RP, Matthews KA, et al. Sex-hormonebinding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation. 2005;111:1242-1249.
30. McCullagh P, Nelder JA. Generalized Linear Models. 2nd ed. London, England: Chapman, Hall/CRC; 1989.
31. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453-1457.
32. Torrens JI, Sutton-Tyrrell K,ZhaoX, et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women?s Health Across the Nation. Menopause. 2009;16:257-264.
33. Kalme T, Koistinen H, Loukovaara M, Koistinen R, Leinonen P. Comparative studies on the regulation of insulin-like growth factorbinding protein-1 (IGFBP-1) and sex hormone-binding globulin (SHBG) production by insulin and insulin-like growth factors in human hepatoma cells. J Steroid Biochem Molec Biol. 2003;86: 197-200.
34. Monaghan PJ, Keevil BG, Stewart PM, Trainer PJ. Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond. J Clin Endocrinol Metabol. 2014;99:4434-4437.
35. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metabol. 2007;92:405-413.
36. Forest J-C, Burtis CA. Development of reference methods and reference materials. International Federation of Clinical Chemistry and Laboratory Medicine website. http://www.ifcc.org/ ifcc-communications-publications-division-%28cpd%29/ifccpublications/ ejifcc-%28journal%29/e-journal-volumes/ejifcc- 2002-vol-13/vol-13-no-3/development-of-reference-methodsand- reference-materials-by-jean-claude-forest-carl-a-burtis/. Accessed October 7, 2015.
37. Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas. 2004;48:39-49.
38. Dumitrescu R, Mehedintu C, Briceag I, Purcarea VL, Hudita D. The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. J Med Life. 2015;8:142-145.